Detalles de la búsqueda
1.
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Future Oncol
; 17(34): 4657-4663, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34775804
2.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(11): 1413-1422, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32979984
3.
Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
Clin Transl Oncol
; 26(3): 597-612, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37651020
4.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
J Thorac Oncol
; 18(11): 1581-1593, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541389
5.
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
Expert Rev Anticancer Ther
; 23(1): 95-106, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36537204
6.
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
J Clin Med
; 12(1)2022 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36614913
7.
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALKâ¯+â¯non-small cell lung cancer (ALTA-1L).
Lung Cancer
; 155: 68-77, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33744781
8.
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
J Clin Med
; 10(19)2021 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34640601
9.
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Cancer Med
; 10(17): 5748-5756, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34405547
10.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
J Thorac Oncol
; 16(12): 2091-2108, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34537440
11.
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group.
J Geriatr Oncol
; 12(3): 410-415, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357975
12.
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
J Clin Oncol
; 38(31): 3592-3603, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780660
13.
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clin. transl. oncol. (Print)
; 26(3): 597-612, mar. 2024. graf
Artículo
en Inglés
| IBECS (España) | ID: ibc-230790
14.
Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway.
Clin Transl Oncol
; 13(2): 77-83, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21324794
Resultados
1 -
14
de 14
1
Próxima >
>>